MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Home・Akciju saraksts・Avita Therapeutics Inc

Avita Therapeutics Inc

Slēgts

4.99 10.89

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.47

Max

5.01

Galvenie mērījumi
By Trading Economics
Ienākumi	1.6M -12M
Pārdošana	554K 18M
Peļņas marža	-65.968
Darbinieki	226
EBITDA	1.6M -9.7M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+54.39% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 7. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-4M 119M
Iepriekšējā atvēršanas cena	-5.9
Iepriekšējā slēgšanas cena	4.99

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

8.83 / 9.77 Atbalsts un pretestība

Avita Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB: Higher Energy Prices to Raise Production, Consumer Costs

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

2026. g. 9. apr. 23:44 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

2026. g. 9. apr. 23:34 UTC

Tirgus saruna

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

2026. g. 9. apr. 23:14 UTC

Tirgus saruna

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

2026. g. 9. apr. 23:14 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 9. apr. 23:07 UTC

Tirgus saruna

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

2026. g. 9. apr. 22:54 UTC

Tirgus saruna

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

2026. g. 9. apr. 22:31 UTC

Galvenie ziņu notikumi

Trump on Truth Social: 'That Is Not the Agreement We Have!'

2026. g. 9. apr. 22:31 UTC

Galvenie ziņu notikumi

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

2026. g. 9. apr. 20:57 UTC

Galvenie ziņu notikumi

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

2026. g. 9. apr. 20:55 UTC

Peļņas

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

2026. g. 9. apr. 20:55 UTC

Peļņas

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

2026. g. 9. apr. 20:55 UTC

Peļņas

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

2026. g. 9. apr. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 9. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. apr. 20:40 UTC

Iegādes, apvienošanās, pārņemšana

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

2026. g. 9. apr. 20:39 UTC

Iegādes, apvienošanās, pārņemšana

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

2026. g. 9. apr. 20:39 UTC

Iegādes, apvienošanās, pārņemšana

Rowan Digital Infrastructure Announces Strategic Recapitalization

2026. g. 9. apr. 20:25 UTC

Iegādes, apvienošanās, pārņemšana

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

2026. g. 9. apr. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 9. apr. 19:30 UTC

Galvenie ziņu notikumi

How Digital Currencies Have Helped Iran -- WSJ

Salīdzinājums

Cenas izmaiņa

Avita Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

54.39% augšup

Prognoze 12 mēnešiem

Vidējais 6.33 USD 54.39%

Augstākais 10 USD

Zemākais 3.5 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Avita Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Avita Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

8.83 / 9.77Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.